PropThink

About the Author PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically complicated companies and equities that are grossly over- or under-valued. We offer regular market coverage and actionable research to PropThink Premium and Premium Plus subscribers.

Celladon Corp (CLDN) May be Forced to Close up Shop Entirely Following Trial Failure and Stock Collapse

It’s one of the most elusive events in biotech: the liquidation. But after a trial failure of epic proportions – and a collapse in …

Alcobra Ltd (ADHD) and Transition Therapeutics Inc (TTHI): Two Failed CNS Drug Trials

Two drugs directed at behavioral disorders failed mid-stage studies on Wednesday morning, said sponsors Alcobra Ltd (NASDAQ:ADHD) and Transition Therapeutics Inc (USA) (NASDAQ:TTHI), yet …

Biotech Beat: Avalanche Biotechnologies Inc (AAVL), bluebird bio Inc (BLUE), Synergy Pharmaceuticals Inc (SGYP) News

Disparate results from two gene therapy developers are worth a mention in this week’s biotech recap. Avalanche Biotechnologies Inc (NASDAQ:AAVL) blew up spectacularly …

Takeaways From The Latest bluebird bio Inc Presentation

This weekend, bluebird bio Inc (NASDAQ:BLUE) and investigators presented much-awaited data for the first Sickle Cell Disease (SCD) patient treated with LentiGlobin (BB305) …

Titan Pharmaceuticals Inc (TTNP)’s Addiction Treatment is Headed to the FDA

Titan Pharmaceuticals, Inc. (OTC MKTS:TTNP)’s implantable device for the treatment of opioid addiction performed as well as standard sublingual buprenorphine tablets in a phase …

Biotech Beat: Oncothyreon Inc (USA), Innate Pharma SA, Regeneron Pharmaceuticals Inc and Merck & Co., Inc. News

Biotech has been in a funk for over a week now, though Friday finished strong. iShares’ NASDAQ Biotechnology ETF (IBB) has been stuck …

Takeways from ASCO 2015: Innate Pharma SA, Oncothyreon Inc (USA), and Affimed NV

By Zack Fink and Jake King Innate Pharma SA (EPA:IPH) presented data from the phase I dose-escalation study of lirilumab in patients with hematologic …

bluebird bio Inc (BLUE)’s Gene Therapy Wows in Sickle Cell Disease

bluebird bio Inc (NASDAQ:BLUE) keeps hitting its marks. The first Sickle Cell patient treated with LengiGlobin, bluebird’s one-time gene therapy product, is producing healthy red …

The Biggest News of the Week in Biotech: Alexion Pharmaceuticals, Inc. (ALXN), Synageva Biopharma Corp (GEVA), Vertex Pharmaceuticals Incorporated (VRTX)

After a mostly red week, stocks gapped higher Friday morning with the latest jobs report. The jobless rate fell to 5.

Alexion Pharmaceuticals, Inc. Puts Up a Premium to Buy Fellow Rare Drug Developer (ALXN)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is buying fellow ultra orphan drug developer Synageva Biopharma Corp (NASDAQ:GEVA) for $8.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts